Reτain
A Study on Efficacy, Safety and Immunogenicity of JNJ-64042056 in Participants with preclinical Alzheimer's Disease
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants With Preclinical Alzheimer's Disease
The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.
Further information for medical professionals can be found here: ClinicalTrials.gov
Study start: Feb/Mar 2025
Ages Eligible for Study: 55 Years to 75 Years (Adult, Older Adult)
Status: recruiting active
Principal Investigator: Dr. Claus Escher
Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE)
Venusberg-Campus 1, Gebäude 99, 53127 Bonn
Contact: